GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosyntech Inc (OTCPK:BSYI) » Definitions » Capital Expenditure

Biosyntech (Biosyntech) Capital Expenditure : $-0.00 Mil (TTM As of Dec. 2009)


View and export this data going back to 2000. Start your Free Trial

What is Biosyntech Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Biosyntech's cash flow for capital expenditures for the three months ended in Dec. 2009 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2009 was $-0.00 Mil.


Biosyntech Capital Expenditure Historical Data

The historical data trend for Biosyntech's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyntech Capital Expenditure Chart

Biosyntech Annual Data
Trend Mar00 Mar01 Mar02 Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.22 -0.21 -0.12 -0.18

Biosyntech Quarterly Data
Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 - - - -

Biosyntech Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyntech (Biosyntech) Business Description

Traded in Other Exchanges
N/A
Address
475 Boulevard Armand-Frappier, Laval, QC, CAN, H7V 4B3
Biosyntech Inc is engaged in developing advanced biotherapeutics thermogels specifically designed for tissue repair and delivery of therapeutic agents. The company's products include BST-CarGel, BST-InPod, BST-DermOn, BST-Ossifil and BST-Ossifix and BST-Disc for intervertebral disc restoration.

Biosyntech (Biosyntech) Headlines

No Headlines